Latest Commercialization News

Red Mountain Mining has produced a high-grade 51.8% antimony concentrate from Oaky Creek with excellent 85% recovery, setting the stage for upcoming drilling to define the resource along a 3km mineralised strike in NSW.

Pacific Edge reported a steep 47% revenue drop in FY26 following Medicare coverage loss but secured a draft Medicare policy covering its Cxbladder tests and raised NZ$25.4 million to fuel growth and commercial execution.

Vectus Biosystems has secured $791,000 through a placement to accelerate its lead fibrosis drug VB0004's Phase IB clinical trial and advance other drug candidates.

1414 Degrees Limited has responded to an ASX price query after its shares jumped from $0.056 to $0.097 in days, confirming no undisclosed information but highlighting progress in aerospace and energy projects.

TrivarX has contracted Beyond Drug Development to drive its Stabl-Im MRI imaging platform into Phase 1 trials, aiming to start safety testing in healthy volunteers by late 2026.

HIQ Limited has locked in non-dilutive funding from the Victorian Government to underpin a $4.9 million project expanding its manufacturing and research footprint in Victoria, supporting its global growth ambitions.

PainChek has secured A$5.5 million via convertible notes to accelerate its US sales expansion and strengthen working capital amid key commercial milestones.

Tivan Limited has formalised binding joint venture agreements with Timor-Leste’s state-owned Murak Rai Timor to develop the Baucau and Ossu copper-gold projects, targeting maiden drilling at Ossu in late 2026.

Bendigo and Adelaide Bank reported a slight increase in its Common Equity Tier 1 ratio to 11.38% for the quarter ended March 2026, driven by net profit and capital inflows. Risk-weighted assets rose 1.75%, largely due to loan portfolio expansion and a new operational risk capital overlay.

Connexion Mobility Ltd has agreed to acquire Hallam Road Automotive in a A$5 million deal expected to immediately lift earnings per share by up to 35% and reduce exposure to foreign exchange fluctuations.

MaxiPARTS has seen activity levels dip due to the Middle East conflict but expects to maintain profit margins through cost controls and a resilient Förch Australia segment.

Vitrafy Life Sciences has achieved a major validation milestone with US Army-backed Phase II results showing its no-wash platelet cryopreservation protocol delivers 94% post-thaw recovery, outperforming existing standards and advancing FDA registration plans.